The initial success of Viagra undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on generic versions presents a uncertain picture. Despite early earnings were substantial, the end of patents and the appearance of cheaper alternatives have diminished market share. Consequently, a thorough analysis of ongoing reve